ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
22 hedge funds and large institutions have $1.82M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 6 closing their positions.
0% more capital invested
Capital invested by funds: $1.82M → $1.82M (+$5.2K)
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
88% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$391K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$75K |
| 3 |
MG
Marex Group
London,
|
+$52.2K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$37.2K |
| 5 |
FIA
FNY Investment Advisers
New York
|
+$29.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$326K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$242K |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$57.8K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$43.5K |
| 5 |
Renaissance Technologies
New York
|
-$31.5K |
ASLN Hedge Fund Activity: Q1 2024 in Review
22 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q1 2024, worth a combined $1.82M — up 0.29% from $1.82M a quarter earlier.
Fund positioning in ASLN was balanced in Q1 2024: 6 funds opened new positions, 6 closed out, 1 added to existing stakes and 8 trimmed.
The largest buyer was Velan Capital Investment Management, opening a new position worth an estimated $391K. The largest seller was UBS Group, exiting entirely with an estimated $326K sold.
- 22 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $1.82M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q1 2024, up 0.29% quarter-over-quarter.
- 6 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q1 2024 and 6 closed out, a net change of 0 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q1 2024 was Velan Capital Investment Management, an estimated $391K added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q1 2024 was UBS Group, an estimated $326K sold.
Based on aggregated 13F filings for Q1 2024.